SFARI Investigator Karen Parker discusses her preclinical and clinical research on the neuropeptides arginine vasopressin and oxytocin as potential biomarkers and treatment strategies for autism spectrum disorder.
SFARI Conversations
SFARI Investigator Dan Feldman discusses the E-I ratio hypothesis in autism and his lab’s recent studies that aimed to test it.
A Conversation with SFARI Bridge to Independence Investigator Seth Shipman SFARI Investigator Seth Shipman discusses his lab’s research on the molecular and cellular mechanisms shaping brain development and how the Bridge to Independence Award is helping him launch his independent research career.
A Conversation with Paul Wang, Deputy Director of Clinical Research Associates Paul Wang, Deputy Director of Clinical Research Associates, L.L.C. (CRA), discusses the research that CRA supports, including human and animal studies using arbaclofen, a potential drug treatment for autism.
A Conversation with SFARI Investigator David Ginty SFARI Investigator David Ginty talks about the links between deficits in the sense of touch, tactile hypersensitivity, and alterations in social behaviors in autism.
A Conversation with Sharmila Banerjee-Basu about SFARI Gene Sharmila Banerjee-Basu, founder and chief scientific officer at MindSpec Inc., discusses SFARI Gene and how it is changing the face of autism genetics research.
A Conversation with SFARI Bridge to Independence Investigator Sung Han SFARI Investigator Sung Han discusses his lab’s work and how the Bridge to Independence Award helped him launch his independent career in autism research.
A Conversation with SFARI Investigator Liqun Luo SFARI Investigator Liqun Luo discusses the neurodevelopmental disorder Smith-Magenis syndrome and his lab’s efforts to understand its underlying biology.
A Conversation with Pamela Feliciano, Scientific Director of SPARK Pamela Feliciano discusses the motivation behind SPARK and insights gained from the initial phases of the project.